title: OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF TIME COURSE OF CHOROIDAL NEOVASCULARIZATION IN RESPONSE TO ANTI-ANGIOGENIC TREATMENT.
abstract: OBJECTIVE
  To use optical coherence tomography (OCT) angiography to monitor the short-term blood flow changes in choroidal neovascularization (CNV) in response to treatment.
  
  
  METHODS
  In this retrospective report, a case of exudative CNV was followed closely with OCT angiography over three cycles of antiangiogenic treatment. Outer retinal flow index, CNV flow area and central macular retinal thickness were measured.
  
  
  RESULTS
  Quantitative measurements of CNV flow area and flow index showed rapid shutdown of flow over the initial 2 weeks, followed by reappearance of CNV channel by the fourth week, preceding fluid reaccumulation at 6 weeks.
  
  
  CONCLUSIONS
  Frequent OCT angiography reveals a previously unknown pattern of rapid shutdown and reappearance of CNV channels within treatment cycles. OCT angiographic changes precede fluid reaccumulation and could be useful as leading indicators of CNV activity that could guide treatment timing. Further studies using OCT angiography in short intervals between antiangiogenic treatments are needed.
authors.affiliation: *Casey Eye Institute, Oregon Health & Science University, Portland, Oregon; and †Centro Oftalmologico Mediterraneo, Rome, Italy.
authors.forename: David
authors.initials: D
authors.lastname: Huang
authors.forename: Yali
authors.initials: Y
authors.lastname: Jia
authors.forename: Marco
authors.initials: M
authors.lastname: Rispoli
authors.forename: Ou
authors.initials: O
authors.lastname: Tan
authors.forename: Bruno
authors.initials: B
authors.lastname: Lumbroso
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001783:Blood Flow Velocity; D002829:Choroid / Q000098:blood supply*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000503:physiopathology*; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D012039:Regional Blood Flow; D012189:Retrospective Studies; D013997:Time Factors; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor